Baird Medical Investment Holdings Limited
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
BDMD · Price history
Price at last available close
$0.25
−$0.55 (-68.65%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Baird Medical Investment Holdings Limited
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
How they make money
Baird Medical generates revenue primarily through the research, development, and sale of minimally invasive medical devices, specifically microwave ablation (MWA) systems and related consumables. The company operates as a medical device manufacturer, selling its products to hospitals and clinics, and incurs costs related to direct materials, staff, production overhead, and distribution.
Products & services
Minimally invasive microwave ablation (MWA) devices and consumables for diagnostics and treatment, with ongoing development of surgical robotic systems and minimally invasive surgical instruments.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
- Hospitals and clinicsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Third-party medical device sourcing — The company utilizes third-party sourcing for medical devices as part of its cost of revenues.Source
Strengths
Risks
- Policy-driven slowdown in Mainland ChinaSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
16
Poor
Financial Strength
33
Business Quality / Moat
4
Management
0
Growth Quality
18
Risk / Durability
29
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
Reverse-split / listing-compliance risk: HIGH
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 55/100
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
No strong positive signal is being highlighted from the currently available summary data.
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for BDMD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BDMD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can BDMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is BDMD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for BDMD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BDMD's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Market Cap
$8.0M
P/E Ratio
-1.3
EPS
$-0.60
52-Week High
$3.70
52-Week Low
$0.66
Beta
-1.14
Shares Outstanding
27.8M
Total Revenue
$56.4M
Total Debt
$14.2M
Dividend
No current dividend
Liquidation Value / Share
$1.25
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BDMD
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingElevated debt risk
Interest coverage is below 2x • Free cash flow is negative • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on BDMD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Market leader in China for thyroid microwave ablation devices and consumables.
- +FDA 510(k)-certified medical device company.
Potential downside factors
- −Debt risk (elevated): Interest coverage is below 2x.
- −Free cash flow is negative.
- −Cash covers less than 20% of total debt.
- −Policy-driven slowdown in Mainland China.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
17
Sep 9, 2026
Change
Unchanged
Current Score
17
Oct 1, 2026
Category Changes
BDMD score was unchanged.
Positive Contributors
- + Revenue improved by 5 points
- + Asset improved by 3.6 points
Projected Score
Projected Score
15
Projected Change
-1.2 points
Preliminary comparable-period financial changes suggest decline of approximately 1.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.25
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.4M | $22.5M | $37.0M | $31.5M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $7.7M | $3.7M | $4.4M | $4.2M | ···· | ···· | ···· | ···· |
| Gross Profit | $48.7M | $18.9M | $32.7M | $27.2M | ···· | ···· | ···· | ···· |
| Research & Development | $25.7M | $20.1M | $6.2M | $4.3M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $37.6M | $24.4M | $10.0M | $11.1M | ···· | ···· | ···· | ···· |
| Operating Expenses | $63.2M | $44.4M | $17.3M | $15.4M | ···· | ···· | ···· | ···· |
| EBITDA | -$11.9M | -$24.5M | $16.2M | $12.9M | ···· | ···· | ···· | ···· |
| Operating Income | -$14.6M | -$25.5M | $15.3M | $11.9M | ···· | ···· | ···· | ···· |
| Interest Expense | $1.4M | $737K | $577K | $284K | ···· | ···· | ···· | ···· |
| Income Before Tax | -$16.6M | -$26.4M | $14.1M | $12.4M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $2.7M | $1.2M | $1.5M | $1.7M | ···· | ···· | ···· | ···· |
| Net Income | -$19.1M | -$27.3M | $12.5M | $10.5M | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.60 | $-0.98 | $0.49 | $0.41 | ···· | ···· | ···· | ···· |
| Basic Shares | 40.98M | 27.79M | 25.56M | 7.58M | ···· | ···· | ···· | ···· |
| Diluted Shares | 40.98M | 27.79M | 25.63M | 7.58M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$9.9M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.00
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-37.0%
Cash Change
-86.7%
Margin Change
+142.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 24.6%. EPS declined 100.0%. Cash declined 86.7%. Total debt declined 37.0%. Net income margin improved by 142.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
Baird Medical Investment (NASDAQ:BDMD) Trading Down 2.5% – Should You Sell?
Rumor Mill · BDMD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial